ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer

PURPOSE: There are clinical unmet needs in predicting therapeutic response and precise strategy for the patient with advanced biliary tract cancer (BTC). We aimed to identify genomic alterations predicting therapeutic response and resistance to gemcitabine and cisplatin (Gem/Cis)-based chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sung Hwan, Cheon, Jaekyung, Lee, Seoyoung, Kang, Beodeul, Kim, Chan, Shim, Hyo Sup, Park, Young Nyun, Jung, Sanghoon, Choi, Sung Hoon, Choi, Hye Jin, Lee, Choong-kun, Chon, Hong Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582529/
https://www.ncbi.nlm.nih.gov/pubmed/37139666
http://dx.doi.org/10.4143/crt.2022.1450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582529/
https://www.ncbi.nlm.nih.gov/pubmed/37139666
http://dx.doi.org/10.4143/crt.2022.1450

Ejemplares similares